PainChek (ASX:PCK) said it is compiling additional information collected from its completed clinical study to address questions from the US Food and Drug Administration, and the submission is expected to be the final step in the firm's US De Novo marketing clearance application, according to a Thursday Australian bourse filing.
The firm said the submission is expected to be the final step in the application and will be submitted before the end of June. It added that there is a commitment by the US FDA for a final decision on De Novo regulatory clearance within 75 days after receiving the submission.
It held a final feedback review meeting with the FDA, focused on addressing the regulator's final questions related to the firm's recent US clinical trial results conducted in New York and Iowa.
The firm also recruited a head of business development for the US market and established integration and reseller agreements with PointClickCare and ElderMark.
The firm's shares fell past 25% in recent trading on Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。